LENZ Therapeutics Inc.

NASDAQ: LENZ · Real-Time Price · USD
31.96
1.66 (5.48%)
At close: Jun 06, 2025, 3:59 PM
32.57
1.89%
After-hours: Jun 06, 2025, 05:22 PM EDT

Company Description

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States.

Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia.

The company is headquartered in Del Mar, California.

LENZ Therapeutics Inc.
LENZ Therapeutics Inc. logo
Country United States
IPO Date Mar 22, 2024
Industry Biotechnology
Sector Healthcare
Employees 6
CEO Evert B. Schimmelpennink

Contact Details

Address:
445 Marine View Avenue
Solana Beach, California
United States
Website https://www.lenz-tx.com

Stock Details

Ticker Symbol LENZ
Exchange NASDAQ
Fiscal Year n/a
Reporting Currency USD
CIK Code 0001815776
CUSIP Number 52635N103
ISIN Number US52635N1037
Employer ID 84-4867570
SIC Code 2836

Key Executives

Name Position
Evert B. Schimmelpennink President, Chief Executive Officer, Secretary & Director
Daniel R. Chevallard CPA Chief Financial Officer
Breianna Bowen Vice President of Human Resources
David Choromanski Vice President of Marketing
Domenick Porfidia Vice President of Sales
James W. McCollum Co-Founder & Director
Kris Gambelin Senior Vice President of Regulatory & Clincal Operations
Marc G. Odrich M.D. Chief Medical Officer
Melissa Rosness Senior Vice President of Manufacturing Operations
Shawn Olsson Chief Commercial Officer

Latest SEC Filings

Date Type Title
May 09, 2025 SCHEDULE 13D/A [Amend] Filing
May 07, 2025 10-Q Quarterly Report
May 07, 2025 8-K Current Report
Apr 28, 2025 ARS Filing
Apr 28, 2025 DEFA14A Filing
Apr 28, 2025 DEF 14A Filing
Apr 15, 2025 8-K Current Report
Apr 14, 2025 EFFECT Filing
Apr 14, 2025 EFFECT Filing
Apr 14, 2025 424B5 Filing